Biopharma: Clinical Trial Pipeline Tracker

Research evidence excerpt

Biopharma: Clinical Trial Pipeline Tracker

Update

July 2, 2026 08:01 PM GMT

Morgan Stanley & Co. LLCMBiopharma | North America Terence C Flynn, Ph.D.

Equity Analyst

Clinical Trial Pipeline Tracker Terence.Flynn@morganstanley.comSean Laaman, Ph.D. +1 212 761-2230

Sean.Laaman@morganstanley.com +1 212 761-4947

We highlight key changes to the clinical trials of companies Michael E Ulz

under coverage occurring from 6/24-7/1. See inside for a full list EquityMike.Ulz@morganstanley.comAnalyst +1 212 761-4650

of changes. Judah C. Frommer, CFA

Judah.Frommer@morganstanley.com +1 212 761-1270

Maxwell SkorMNew Trials ( Exhibit 1 ) Equity Analyst

Maxwell.Skor@morganstanley.com +1 212 761-4804

• Argenx: The company has initiated a Ph2 study (NCT07673627) to Evaluate Chris Yu, J.D., Ph.D.

the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Equity Analyst

Chris.L.Yu@morganstanley.com +1 212 761-2535

Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis Alexander Yevdokimov, Ph.D.

• Eli Lilly: The company has initiated a Ph3 study (NCT07668336) of Research Associate

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric

Connor M Massari

Participants With Type 2 Diabetes Equity Analyst

• Regeneron: The company has initiated a Ph1/2 study (NCT07675824) of Connor.Massari@morganstanley.com +1 212 761-2417

Michael H Riad, Ph.D.

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Research Associate

Hypertension Michael.Riad@morganstanley.com +1 212 761-1309

Katherine Sun

• Rhythm Pharmaceuticals: The company has initiated a Ph4 trial Research Associate

(NCT07674290) of Real-World Effects of MC4R Agonist Therapy in BBS and Katherine.Sun@morganstanley.com +1 212 761-5968